Impact of baseline symptoms and health status on COPD exacerbations in the FLAME study.

ABSTRACT:

Background

COPD is a heterogeneous disease and patients may respond differently to therapies depending on baseline symptom burden.

Methods

This post-hoc analysis from the 52-week FLAME study investigated the impact of baseline symptom burden in terms of health status, dyspnoea, bronchitis status, eosinophil levels and smoking status on the subsequent risk of moderate or severe exacerbations. Health status was measured by St. George's Respiratory Questionnaire (SGRQ) score (higher ≥46.6 and lower < 46.6) and COPD Assessment Test (CAT) score (higher ≥17 and lower < 17); dyspnoea and bronchitis were assessed via an electronic diary (eDiary). Differential response to once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg versus twice-daily salmeterol/fluticasone (SFC) 50/500 

SUBMITTER: Mackay AJ 

PROVIDER: S-EPMC7179005 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature